Actinium Pharmaceuticals, Inc (ATNM) is a publicly traded Healthcare sector company. As of September 17, 2026, ATNM trades at $1.25 with a market cap of $39.30M and a P/E ratio of -1.16. ATNM moved -2.10% today. Year to date, ATNM is -8.82%; over the trailing twelve months it is -25.30%. Its 52-week range spans $0.74 to $2.41. Analyst consensus is moderatebuy with an average price target of $3.50. Rallies surfaces ATNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks ATNM insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $1.25 |
| Market Cap | $39.30M |
| P/E Ratio | -1.16 |
| EPS | $-1.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.41 |
| 52-Week Low | $0.74 |
| Volume | 49.16K |
| Avg Volume | 0 |
| Revenue (TTM) | $90.00K |
| Net Income | $-33.89M |
| Gross Margin | 0.00% |
2 analysts cover ATNM: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is moderatebuy. Average price target: $3.50.